No products in the cart.
Rabbit Polyclonal Phospho-MITF (S180) antibody (STJ90470)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IHC, ELISA
Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:10000;
Recommended protocols: check protocols
Click or hover above images to see image description for MITF (phospho Ser180) Polyclonal Antibody.
Check alternative names for the antibodyExpand
MITF antibody, BHLHE32 antibody,|BHLHE32 antibody|bHLHe32 antibody|Class E basic helix-loop-helix protein 32 antibody|CMM8 antibody|Homolog of mouse microphthalmia antibody|Mi antibody|Microphthalmia associated transcription factor antibody|Microphthalmia, mouse, homolog of antibody|Microphthalmia-associated transcription factor antibody|MITF antibody|MITF_HUMAN antibody|mitfa antibody|nacre antibody|WS2 antibody|WS2A antibody|z3A.1 antibody|Anti-MiTF antibody [C5] – ChIP Grade (ab12039)
SCBT cat No: sc-52938|sc-71588|sc-71587|sc-11002|sc-56725|sc-56726|sc-25386|sc-10999|sc-56433|
MITF (phospho Ser180) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Monkey
Phospho-MITF (S180) Polyclonal Antibody detects endogenous levels of MITF protein only when phosphorylated at S180.
Synthesized phospho-peptide derived from MITF (phospho Ser180) at AA range 120-200
WB, IHC, ELISA
|Recommended dilution|| |
WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:10000;
|Molecular weight|| |
MITF (phospho Ser180) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
MITF (phospho Ser180) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Microphthalmia-associated transcription factor antibody, Class E basic helix-loop-helix protein 32 antibody, bHLHe32 antibody
|Protein names|| |
Microphthalmia-associated transcription factor , Class E basic helix-loop-helix protein 32 , bHLHe32
|Protein function|| |
Transcription factor that regulates the expression of genes with essential roles in cell differentiation, proliferation and survival. Binds to symmetrical DNA sequences (E-boxes) (5′-CACGTG-3′) found in the promoters of target genes, such as BCL2 and tyrosinase (TYR). Plays an important role in melanocyte development by regulating the expression of tyrosinase (TYR) and tyrosinase-related protein 1 (TYRP1). Plays a critical role in the differentiation of various cell types, such as neural crest-derived melanocytes, mast cells, osteoclasts and optic cup-derived retinal pigment epithelium.
|Protein tissue specificity|| |
Isoform M is exclusively expressed in melanocytes and melanoma cells. Isoform A and isoform H are widely expressed in many cell types including melanocytes and retinal pigment epithelium (RPE). Isoform C is expressed in many cell types including RPE but not in melanocyte-lineage cells. Isoform Mdel is widely expressed in melanocytes, melanoma cell lines and tissues, but almost undetectable in non-melanoma cell lines.
|Involvement in disease|| |
Waardenburg syndrome 2A (WS2A) [MIM:193510]: WS2 is a genetically heterogeneous, autosomal dominant disorder characterized by sensorineural deafness, pigmentary disturbances, and absence of dystopia canthorum. The frequency of deafness is higher in WS2 than in WS1. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Waardenburg syndrome 2, with ocular albinism, autosomal recessive (WS2-OA) [MIM:103470]: A disorder characterized by the association of features typical of Waardenburg syndrome type 2 with ocular albinism. Patients manifest reduced visual acuity, albinotic fundus, deafness, hypomelanosis. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Tietz syndrome (TIETZS) [MIM:103500]: Autosomal dominant disorder characterized by generalized hypopigmentation and profound, congenital, bilateral deafness. Penetrance is complete. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Melanoma, cutaneous malignant 8 (CMM8) [MIM:614456]: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. . Note: Disease susceptibility is associated with variations affecting the gene represented in this entry.
|Protein sequence and domain|| |
Belongs to the MiT/TFE family. / Contains 1 bHLH (basic helix-loop-helix) domain.
|Protein post-translational modifications|| |
Phosphorylation at Ser-405 significantly enhances the ability to bind the tyrosinase promoter. Phosphorylated at Ser-180 and Ser-516 following KIT signaling, trigerring a short live activation: Phosphorylation at Ser-180 and Ser-516 by MAPK and RPS6KA1, respectively, activate the transcription factor activity but also promote ubiquitination and subsequent degradation by the proteasome. / Ubiquitinated following phosphorylation at Ser-180, leading to subsequent degradation by the proteasome. Deubiquitinated by USP13, preventing its degradation.
|Protein cellular localization|| |
AntibodyPlus can customize MITF (phospho Ser180) Antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: